Scafuri, Luca http://orcid.org/0000-0002-7410-8300
Buonerba, Carlo
Di Lauro, Vincenzo
Tortora, Vincenzo
Cascella, Marco
Liguori, Luigi
Sciarra, Antonella
Sabbatino, Francesco
Diana, Anna
Marra, Antonio
Tarantino, Paolo
Trapani, Dario
Giuliano, Mario
Arpino, Grazia
Curigliano, Giuseppe
Di Lorenzo, Giuseppe
Article History
Received: 21 March 2024
Accepted: 3 June 2024
First Online: 28 June 2024
Declarations
:
: Luca Scafuri and Carlo Buonerba have received honoraria as speakers from Genetic Spa. Vincenzo Di Lauro has received speaker’s honoraria from Amgen, Seagen, Wavepharma, Genetic, Veracyte, Novartis, and Accord. Paolo Tarantino reports research funding (to institution) from AstraZeneca and has served as advisor/consultant for AstraZeneca, Daiichi-Sankyo, Gilead, Novartis, Roche, Genentech and Lilly. Giuseppe Di Lorenzo is an Editorial Board member of<i> Oncology and Therapy</i>; he was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Antonio Marra has received honoraria as a consultant, advisor or speaker from Roche and Menarini/Stemline; and has received travel and accommodation support from AstraZeneca. Vincenzo Tortora, Marco Cascella, Luigi Liguori, Antonella Sciarra, Francesco Sabbatino, Anna Diana, Dario Trapani, Mario Giuliano, Grazia Arpino and Giuseppe Curigliano have nothing to disclose.
: While this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, ethical considerations are paramount for any future study. Should this research progress, obtaining informed consent, ensuring participant confidentiality, and securing Institutional Review Board (IRB) approval will be essential. The research will also adhere to the principles outlined in the Declaration of Helsinki and be registered with a relevant clinical trial registry.